A Multicenter, Open-Label Extension Study To Evaluate The Long-Term Safety and Tolerability Of Faricimab In Patients With Neovascular Age-Related Macular Degeneration
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 1280 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Masking Description: | The first 12 weeks of this study will be a masked period (to transition from the multi-arm parent studies) during which participants may receive either faricimab or sham injection. Participants and physicians will be masked only to the faricimab treatment interval. After the Week 12 treatment procedure, this study will follow an open-label design. The BCVA examiner will remain masked for the duration of this long-term extension study. |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (AVONELLE-X) |
| Actual Study Start Date : | April 19, 2021 |
| Estimated Primary Completion Date : | August 9, 2024 |
| Estimated Study Completion Date : | August 9, 2024 |
